1. Home
  2. ANAB vs SWIN Comparison

ANAB vs SWIN Comparison

Compare ANAB & SWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • SWIN
  • Stock Information
  • Founded
  • ANAB 2005
  • SWIN 2017
  • Country
  • ANAB United States
  • SWIN Hong Kong
  • Employees
  • ANAB N/A
  • SWIN N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • SWIN
  • Sector
  • ANAB Health Care
  • SWIN
  • Exchange
  • ANAB Nasdaq
  • SWIN Nasdaq
  • Market Cap
  • ANAB 630.2M
  • SWIN 541.0M
  • IPO Year
  • ANAB 2017
  • SWIN 2023
  • Fundamental
  • Price
  • ANAB $21.08
  • SWIN $2.63
  • Analyst Decision
  • ANAB Buy
  • SWIN
  • Analyst Count
  • ANAB 10
  • SWIN 0
  • Target Price
  • ANAB $48.00
  • SWIN N/A
  • AVG Volume (30 Days)
  • ANAB 515.2K
  • SWIN 1.7M
  • Earning Date
  • ANAB 11-04-2025
  • SWIN 06-30-2025
  • Dividend Yield
  • ANAB N/A
  • SWIN N/A
  • EPS Growth
  • ANAB N/A
  • SWIN N/A
  • EPS
  • ANAB N/A
  • SWIN N/A
  • Revenue
  • ANAB $123,164,000.00
  • SWIN $3,316,000.00
  • Revenue This Year
  • ANAB $11.40
  • SWIN $29.79
  • Revenue Next Year
  • ANAB $8.17
  • SWIN $54.60
  • P/E Ratio
  • ANAB N/A
  • SWIN N/A
  • Revenue Growth
  • ANAB 304.17
  • SWIN N/A
  • 52 Week Low
  • ANAB $12.21
  • SWIN $1.16
  • 52 Week High
  • ANAB $39.50
  • SWIN $5.09
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 47.97
  • SWIN 38.47
  • Support Level
  • ANAB $17.11
  • SWIN $2.45
  • Resistance Level
  • ANAB $24.07
  • SWIN $2.90
  • Average True Range (ATR)
  • ANAB 1.49
  • SWIN 0.46
  • MACD
  • ANAB -0.03
  • SWIN -0.04
  • Stochastic Oscillator
  • ANAB 57.03
  • SWIN 11.29

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About SWIN Solowin Holdings

Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.

Share on Social Networks: